Kyunghyun Cho co-founded Prescient Design, acquired by Genentech, and worked there until January 2026

kyunghyun-choprescient-designgenentechperson-bridgedrug-discovery

Per his own homepage, Kyunghyun Cho — an NYU professor known in this vault as a co-author of the "Neural Neural Scaling Laws" line of work (claim-hu-2026-no-independent-corroboration-found-as-of-2026-10-24, claim-lourie-2025-six-category-downstream-scaling-taxonomy) — spent 2021 through January 2026 inside industrial drug discovery: "Early 2021, he co-founded Prescient Design which was acquired by Genentech late 2021. Since then, he served as an Executive Director of Frontier Research and a Senior Fellow at Genentech until January 2026." Prescient Design is a machine-learning-driven protein/antibody-design startup; its acquisition by Genentech less than a year after founding put an academic scaling-laws theorist directly inside a pharmaceutical company's research arm for nearly five years.

This is the biographical fact that makes Cho's machine-translation-era analogy for AI drug discovery more than an outsider's armchair comparison — he was diagnosing a field he was working inside at the time of writing. The post is datelined 2 July 2025: roughly four and a half years into the Prescient-then-Genentech stretch, and about seven months before the formal role ended in January 2026. The critique is a view from inside the lab, not a parting verdict from outside it. (Corrected 2026-10-28: the promotion wording said the piece was written "the same month … that his formal role there ended"; the post's own dateline and the homepage's "until January 2026" are about seven months apart.)